Bayer HealthCare Pharmaceuticals Inc.

Improving patient outcomes is at the heart of Bayer’s long-standing commitment to addressing unmet medical needs in patients.  Bayer’s U.S. Cardiovascular and Renal Franchise brings therapeutic advances to patients that cover a wide range of approaches for cardiovascular, pulmonary, and renal diseases or conditions including heart failure (HF), pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH), and chronic kidney disease (CKD) in patients with type 2 diabetes (T2D).

Follow on social Media
Bayer Phase IV Study